Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Muneer Abidi, Barbara Ann Karmanos Cancer Institute
ClinicalTrials.gov Identifier:
NCT00482846
First received: June 4, 2007
Last updated: April 14, 2014
Last verified: April 2014

June 4, 2007
April 14, 2014
June 2007
October 2011   (final data collection date for primary outcome measure)
Maximum tolerated dose of melphalan when treated with palifermin to prevent mucositis [ Time Frame: Days -5, -4, -3, 2, +1, +2 and +3 ] [ Designated as safety issue: Yes ]
Maximum tolerated dose of melphalan
Complete list of historical versions of study NCT00482846 on ClinicalTrials.gov Archive Site
  • Dose-limiting toxicity [ Time Frame: Days -5, -4, -3, 2, +1, +2 and +3 ] [ Designated as safety issue: Yes ]
  • Evaluate the efficacy of Palifermin as a cytoprotective agent in reducing incidence and duration of Grade 3 and 4 mucositis due to high dose Melphlan [ Time Frame: Day -5 to Day +28 ] [ Designated as safety issue: Yes ]
  • Overall response [ Time Frame: At Day 28 and Day100 after autologous transplant when treated with combination of palifermin and Melphalan ] [ Designated as safety issue: No ]
  • Reduction in incidence and duration of mucositis [ Time Frame: Days -5 to Day +28 ] [ Designated as safety issue: Yes ]
  • Dose-limiting toxicity
  • Mucositis and diarrhea
  • Overall response
  • Reduction in incidence and duration of mucositis
  • Quality of life
Not Provided
Not Provided
 
Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma
Phase I Dose Escalation Trial of High Dose Melphalan Conditioning Regimen With Palifermin for Cytoprotection Followed by Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma

RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Keratinocyte growth factors, such as palifermin, may help prevent symptoms of mucositis, or mouth sores, in patients receiving melphalan before a peripheral stem cell transplant for multiple myeloma.

PURPOSE: This phase I trial is studying the side effects and best dose of melphalan when given together with palifermin in treating patients undergoing an autologous peripheral stem cell transplant for stage II or stage III multiple myeloma.

OBJECTIVES:

Primary

  • Determine the maximum tolerated dose of high-dose melphalan when administered with palifermin in patients undergoing autologous peripheral blood stem cell transplantation for stage II or III multiple myeloma.

Secondary

  • Assess overall response (complete and partial response and stable disease) in these patients at 28 and 100 days post-transplantation.
  • Assess the efficacy of palifermin as a cytoprotective agent in reducing incidence and duration of mucositis in patients treated with this regimen.
  • Assess patient-reported outcomes and impact of palifermin on quality of life of these patients.
  • Assess the qualitative and quantitative toxicities of this regimen in these patients.

OUTLINE: This is a dose-escalation study of melphalan. Patients are stratified according to creatinine clearance (normal vs < 60 mL/min).

Patients receive high-dose melphalan IV on day -2 and palifermin IV on days -5 to -3 and 1-3. Patients undergo autologous peripheral blood stem cell transplantation on day 0.

In each stratum, cohorts of 3-6 patients receive escalating doses of melphalan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients complete questionnaires about overall health, mouth and throat soreness (MTS), and activity limitations due to MTS once daily on days -5 to 28.

After completion of study treatment, patients are followed at days 28 and 100 and then periodically thereafter.

Interventional
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
  • Mucositis
  • Multiple Myeloma
  • Biological: Palifermin
    Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is >40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3
    Other Name: Kepivance
  • Drug: melphalan

    Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:

    Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;

    Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. <60)adm. via I.V.:

    Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;

    Other Name: Alkeran
  • Other: questionnaire administration
    Day -5 to Day +28
  • Procedure: autologous peripheral blood stem cell transplantation
    Day 0
  • Other: quality-of-life assessment
    Day -5 to Day +28
Experimental: Palifermin & Melphalen

Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is >40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3

Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:

Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;

Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. <60)adm. via I.V.:

Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;

Interventions:
  • Biological: Palifermin
  • Drug: melphalan
  • Other: questionnaire administration
  • Procedure: autologous peripheral blood stem cell transplantation
  • Other: quality-of-life assessment
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
38
September 2012
October 2011   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosis of multiple myeloma

    • Stage II or III disease
  • Must have undergone successful stem cell mobilization (≥ 2.0 x 10^6 CD34+ cells/kg)
  • No oral lesions from any other etiology
  • No unhealed mucositis from induction treatment

PATIENT CHARACTERISTICS:

  • ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%
  • Amylase and lipase normal
  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • AST and ALT ≤ 3 times ULN
  • Creatinine normal (stratum 1 only)
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No HIV positivity
  • No history of allergic reaction attributed to melphalan
  • No uncontrolled illness, including, but not limited to, any of the following:

    • Ongoing or active infection
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia
  • No psychiatric illness or social situation that would preclude study compliance
  • No hepatitis B or C positivity
  • No prior or concurrent pancreatitis
  • No known sensitivity to any of the study drugs, including E. coli-derived products

PRIOR CONCURRENT THERAPY:

  • Prior bone marrow or stem cell transplantation allowed
  • No prior palifermin
  • More than 30 days since prior investigational agents
  • No concurrent dialysis
  • No concurrent amifostine
  • No concurrent prophylactic oral cryotherapy during melphalan administration
  • No concurrent mouthwash solutions containing any of the following:

    • Chlorhexidine
    • Hydrogen peroxide
    • Diphenhydramine hydrochloride
  • No concurrent recombinant interleukin-11 or sargramostim (GM-CSF)
  • No concurrent sucralfate in suspension form

    • Sucralfate tablets allowed
  • No concurrent povidone-iodine rinses
  • No concurrent glutamine as a prophylactic agent for mucositis
  • No other concurrent investigational agents
  • No concurrent antithymocyte globulin suppression or alemtuzumab
  • No concurrent rituximab
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00482846
CDR0000547155, P30CA022453, WSU-2006-119
Yes
Muneer Abidi, Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Principal Investigator: Muneer H. Abidi, MD Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP